BKM120 in Cancers With PIK3CA Activating Mutations

Breast Cancer Clinical Trial

Official title:

An Open Label, Phase II Trial of BKM120 in Cancers With PIK3CA Activating Mutations

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT01501604
• Other study ID #: 11-211
• Status: Withdrawn
• Phase: Phase 2
• First received: December 27, 2011
• Last updated: September 16, 2015
• Start date: January 2012
• Est. completion date: August 2013

Study information

• Verified date: September 2015
• Source: Massachusetts General Hospital
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

In people whos cancers have a PIK3CA mutation, this trial will be evaluating the drug BKM120 as a possible treatment. BKM120 works by blocking the phosphatidylinositol-3-kinase (PI3K)pathway, thereby inhibiting tumor growth and survival.

The purpose of this study is to learn if the study drug BKM120 can shrink or slow the growth of your tumor. The safety of BKM120 will also be studied. Your physical state, symptoms, change in the size of your tumor, and laboratory findings obtained while you are on study will help the research team decide if BKM120 is safe and effective in patients with advanced cancers.

Description:

Subjects enrolled in this study will receive BKM120 once daily, orally, in cycles of 28 days.

During Cycles 1 and 2, the following tests and procedures will be done on days 1 and 15:

• physical exam

• performance status

• blood tests

• pregnancy test (if applicable)

• neuropsychiatric assessments

Starting at Cycle 2 and then every other cycle thereafter (approximately every 8 weeks) tumor assessment will be performed by CT/MRI or PET scan. A chest x-ray will also be performed every 8 weeks.

Beginning with Cycle 3, the following tests/procedures will be performed on Day 1 of each cycle:

• physical exam

• performance status

• blood tests

• neuropsychiatric assessments

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: August 2013
• Est. primary completion date: August 2013
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• At least 1 site of measurable disease

• Life expectancy >/= 12 weeks

• Adequate marrow and organ function

• Diagnosis of lung cancer, breast cancer, colorectal cancer, cholangiocarcinoma, gastric cancer, pancreatic cancer, prostate cancer, uterine cancer, ovarian cancer, esophageal cancer, or head and neck cancer

• Pathologically documented, definitively diagnosed, advanced solid tuor that is refractory to standard treatment, for which no standard therapy is available, or the subject refuses standard therapy

• Cancer must have at least one of the following PIK3CA mutations: E542K, E545K, H1047R, H1047L. The PIK3CA mutation must be documented in a CLIA approved laboratory

Exclusion Criteria:

• Prior treatment with a P13K inhibitor

• Known hypersensitivity to BKM120 or its excipients

• Untreated brain metastases

• Acute or chronic liver, renal disease or pancreatitis

• Currently treated with drugs known to be moderate and strong inhibitors or inducers of isoenzyme CYP3A

• Diarrhea >/= CTCAE grade 2

• Any concurrent severe and/or uncontrolled medical condition

• Active cardiac disease

• History of cardiac dysfunction

• Poorly controlled diabetes mellitus or steroid-induced diabetes mellitus

• Significant symptomatic deterioration of lung function

• Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of BKDM120 (e.g., ulcerative diseases, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, or small bowel resection)

• Currently taking therapeutic doses of warfarin sodium or any other coumadin-derivative anticoagulant

• Pregnant or breast-feeding

• Known diagnosis of HIV infection

• History of another malignancy within 3 years, except cured basal cell carcinoma of the skin or excised carcinoma in situ of the cervix

• Unable to swallow the medication in its prescribed form

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Breast Cancer
• Cholangiocarcinoma
• Colorectal Cancer
• Lung Cancer
• Solid Tumors

Intervention

Drug:
• BKM120
100 MG PO QD in cycles of 28 days

Locations

Country	Name	City	State
n/a

Sponsors (2)

Lead Sponsor	Collaborator
Massachusetts General Hospital	Novartis Pharmaceuticals

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Response Rate	Objective Response Rate (CR or PR) by RECIST 1.1 criteria	2 years	No
Secondary	Clinical Benefit Rate	Clinical Benefit Rate (CR, PR, or SD) by RECIST 1.1 criteria	2 years	No
Secondary	Survival	Progression Free Survival (PFS)	2 years	No
Secondary	Clinical Benefit	Determine if the presence of specific co-existing mutations may influence clinical benefit from BKM120	2 years	No